Pfizer is recalling 3,546 vials of Bleomycin for Injection, USP, 15 units per vial, due to the presence of glass particulate matter. This sterile injectable medication, distributed by Hospira, Inc., is used in the treatment of various cancers. Injecting a medication contaminated with glass fragments can cause serious health issues, including blood clots or inflammation of the blood vessels. Consumers who have questions or concerns about this recall should contact their healthcare provider or pharmacist.
The injection of glass particles into the bloodstream can lead to local irritation, inflammation, or serious systemic complications such as blood clots that may travel to vital organs like the heart, lungs, or brain. While no injuries have been reported, the manufacturer has classified this risk as critical due to the potential for severe health consequences.
Distributed by Hospira, Inc., Lake Forest, IL 68045.
: “Bleomycin for Injection, USP, 15 Units Single-Dose ONCO-TAIN™ Glass Fliptop Vial, NDC 61703-332-18”
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · FDA Press Release · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.